# Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

> **NCT04099836** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 7 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04099836
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-09
- **Primary completion:** 2022-11-13
- **Final completion:** 2023-06-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099836, "Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04099836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*